

AD _____

Award Number: W81XWH-11-1-0756

TITLE: Pediatric Glioblastoma Therapies Based on Patient-Derived Stem Cell Resources

PRINCIPAL INVESTIGATOR: Patrick Paddison

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center

REPORT DATE: October 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2013		2. REPORT TYPE Annual		3. DATES COVERED 1 Sep 2012 - 31 Aug 2013	
4. TITLE AND SUBTITLE Pediatric Glioblastoma Therapies Based on Patient-Derived Stem Cell Resources				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-11-1-0756	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Patrick Paddison E-Mail: paddison@fhcrc.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fred Hutchinson Cancer Research Center Seattle, WA 98109-4433				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Gliomas comprise ~60% of cases among pediatric brain tumors. To date, there are few resources available to study and manipulate pediatric brain tumor cells, to evaluate whether pediatric tumor will have fundamental different responses to the new therapeutic regimes. Since glioma stem cell lines have been successfully isolated from adults, in this proposal we aim to isolate and characterize GSC populations from pediatric patients. In the past two years we have successfully derived and cultured eight patient-derived pediatric glioma stem cell lines. In the past year we have continued molecular and phenotypic characterization of these lines. This characterization included analysis of gene expression and patient-specific gene mutations, and also proof-of-concept shRNA screens. In addition we have begun to identify candidate therapeutic targets using the pediatric GBM isolates. So far, this effort has led to two promising candidate molecules for precision pediatric brain tumor therapeutics.					
15. SUBJECT TERMS Glioblastoma multiforme , glioma stem cell, brain tumor-initiating cell, pediatric brain tumor, RNAi, functional genetics					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 11	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

INTRODUCTION	4
BODY	4
KEY RESEARCH ACCOMPLISHMENTS	6
REPORTABLE OUTCOMES	6
CONCLUSION	7
APPENDICES	NONE
REFERENCES	8
SUPPORTING DATA	9

PI: Patrick J. Paddison, PhD, Fred Hutchinson Cancer Research Center
Progress Report September 2013 (YEAR 2)

INTRODUCTION

Glioblastoma multiforme (GBM) is the most aggressive and common form of brain cancer in adults, and is among the deadliest cancers with a median survival period of 12-14 months. GBM tumors appear to be hierarchically organized suggestive of a cancer stem cell origin. Consistent with this notion, tumor-initiating, glioma stem cells (GSC) have recently been isolated that retain the development potential and specific genetic alterations found in the patient's tumor. When used to generate tumors in the cortex of mice, these cells give rise to patient-specific molecular signatures and histological features. Gliomas comprise ~60% of cases among pediatric brain tumors. To date, there are few resources available to study and manipulate pediatric brain tumor cells, to evaluate whether pediatric tumors will have fundamental different responses to the new therapeutic regimes. Since glioma stem cell lines have been successfully isolated from adults, in this proposal we aim to isolate GSC population from pediatric patients. Through collaboration with Dr. Xiao-Nan Li at Texas Children's Hospital, Dr. Paddison's group has access to ten orthotopic mouse lines harboring tumors derived from ten different pediatric glioma cases. In these orthotopic xenograft models, patient tumor samples are injected directly into the cortex of recipient NOD-SCID mice, where upon the patient tumor regrows with similar molecular and pathological characteristics observed in the tumor of origin. In this grant, we are deriving and characterizing pediatric GSC lines and assessing whether they diverge from adult GSCs with respect to genes and networks required for proliferation and survival.

BODY

In this proposal, Dr. Paddison takes a step towards defining new therapeutic strategies for pediatric glioma by applying adult GSC isolation and culture techniques to derive pediatric glioma stem cells and then assessing whether pediatric isolates diverge from adult GBM patients with respect to genes and networks required for proliferation and survival. There are three specific aims:

1. To isolate pediatric glioma stem cell populations in defined monolayer growth culture conditions.
2. To perform molecular and phenotypic characterization of pediatric glioma stem cell isolates.
3. To determine whether adult and pediatric GSCs share common proliferation and survival networks.

During year 2, excellent progress has been made towards the goals of this grant. However, while the overall statement of work has not changed in year two, some aspects of the work plan have progressed slower, while others have progressed faster, as is the norm with biological experiments, especially with patient cancer isolates. **Thus, we present progress towards both year 2 and year 3 goals below that occurred during year 2 (with Aim 1 having been completed)**

Progress on Aim 2

The overall goal of this grant is to create tractable pediatric glioma tumor models and to use them to identify new therapeutic approaches to treat this terrible disease. During year 2, we have been able to further characterize 3 of the 8 pediatric patient lines derived in year 1, including 1502 (GBM; 4y8mo / female), 1406 (GBM; 4y / female), and 3752 (GBM; 5y / female). While each of the eight isolates can grow as neurospheres (Year 1 Progress report Table 1), only these three isolates can be converted to robust monolayer cultures and grown in a tractable manner with doubling times <60 hrs, similar to our adult

GSCs. As a result, we have chosen to focus on these for further inclusion in molecular characterization and functional genetic experiments in Aims 2 and 3.

In aim 2, we proposed to perform molecular and phenotypic characterization of pediatric isolates from Aim 1 to determine whether they: (1) harbor glioma stem cell characteristics; (2) fall into one or more adult GBM subclasses; and (3) are capable of initiating tumors. We have made significant progress for this aim.

In year 1 we began to assess pediatric isolates in terms of their ability to form tube-like endothelial structures in vitro, which may be important for tumor-microenvironment interactions and represent a novel tumor-specific lineage [6,7]. So far the 1406 but not the 1502 line shows ability to differentiate and form tube-like structures in endothelial tube formation assays. We've also started access degree of expression of endothelial cell markers such as CD105, which may correlate with tumor aggressiveness in adult GBMs. In year 2, we extended this analysis to include differentiation conditions that promote GBM-derived pericytes [1] that interact with endothelial cells and may be a key feature of GBM differentiation programs. Through a collaboration with Dr. Shideng Bao (Cleveland Clinic) we have begun to assess the ability of the pediatric glioma cell lines to convert into pericytes using Dr. Bao's fluorescent reporter systems [1] and have confirmed expression of pericyte-specific genes in pediatric glioma stem cell lines. These results suggest that similar to adult brain tumors pediatric ones have the ability to form pericytes (**Figure 1**).

In year 1 we were in the process of classifying pediatric GSC isolates according to the scheme proposed for adult GBMs [8,9] based on an 840 gene list predictive of Proneural, Neural, Classical and Mesenchymal subtypes. In year 2 we've completed refining the method for determine subtype and have applied it to pediatric isolates 1406 and 1502 (**Figure 2**). The method we developed and refined (yr 1-2) is as follows. We performed RNA-seq on GSC cultures (n=3) using an Illumina HiSeq 2000 according to the manufacturer's instructions (FHCRC Genomics Shared Resource). RNA-Seq reads are then aligned to the GRCh37/hg19 assembly using Tophat [11] and counted for gene associations against the UCSC genes database with HTSeq, a python package for analysis of high-throughput sequencing data [12]. The R language of statistical computing is then used for further analysis [13]. All data is combined and normalized using a trimmed mean of M-values (TMM) method from the R package, edgeR [14-16]. Normalized counts are then log transformed, and the means across all the cell lines were used to calculate relative gene expression levels. The GSC line data is then clustered using a Manhattan distance complete-linkage method to establish leaflets. Previously 173 glioma cell lines were subtyped using the expression of 840 signature genes [8]. Our samples are clustered using 790 of these genes. The associations of our cell lines to those in publication are determined by minimum Manhattan distance to expression centroids produced by ClANC. If a gene is expressed consistently in a particular subtype by absolute distance, then that is counted as a 1 and the number of associated genes in each category is summed. As a validation, the four subtypes are clearly distinguished when the method is applied to the 173 glioma lines described previously [8]. Using this analysis 1406 is "proneural" and 1502 is "mesenchymal" (**Figure 2**).

In the past year, we have also performed exome-sequencing on 1502 and potentially discovered novel mutation spectra different than that for adult glioma isolates. We have now started the process of building significant work flows (in collaboration with Dr. Jun Zhu (MSSM)) to weed out common single-nucleotide polymorphisms and also to using RNA-seq data to predict copy number variation from RNA-seq data of the pediatric lines.

Progress on Aim 3

In aim 3, we proposed to examine RNAi hits that have been validated as essential for adult GSC proliferation or survival in pediatric GSC isolates. In addition, we further proposed to perform preliminary shRNA "shotgun" screens to be performed on two pediatric GSC lines to obtain functional genetic "fingerprints" to compare to adult GSCs screen results. Last year we reported testing several candidate glioma-lethal targets in pediatric glioma isolates, including two that have been recently published BUB1B [17] and PHF5A [18]. Of these we found that pediatric isolates had variation in requirement for BUB1B but not for PHF5A. Using RNA-seq and exome-seq data for our isolates, in collaboration with Jun Zhu (MSSM, NY),

we have discovered both gene expression and mutation signatures that may correlate with BUB1B sensitivity. If successful, we may be able to predict sensitivity to BUB1B inhibition based on molecular signature of a handful of genes (e.g., 1-10) – hopefully in year 3 we will have further answers.

In addition, from the results published in [18] we have found a novel vulnerability in ZNF131 for pediatric isolate 1502 (**Figure 3**). According to motif analysis ZNF131 encodes a BTB/POZ zinc finger protein, and thus might act as a transcriptional regulator. We are currently pursuing the hypothesis that ZNF131 transcriptionally regulates HAUS5, a component of Augmin protein complex, and that this regulation is crucial for maintenance of 1502 and other tumor isolate viability. In year 3 we will present additional data regarding this hypothesis and biology.

In addition have also performed RNAi screens targeting 319 epigenetic factors in adult and pediatric glioma isolates and also in neural stem cells, a non-transformed candidate cell of origin control for gliomas [17,18]. Our preliminary results from this screen are presented in **Table 1**. The goal of this screen is to identify key epigenetic factors that are required for maintenance of expression of survival and self-renewal circuits in adult and pediatric glioma stem cells. However, this functional set has the added advantage of targeting genes with drugable enzymatic activities. As a result we are already collaborating with Cheryl Arrowsmith of the Structural Genomics Consortium at University of Toronto, who has helped develop cell permeable inhibitors of the Set1-like multiprotein histone methyltransferase complex, two members of which scored in our screen. However, we have noticed some noise in our data analysis and may end up having to redo this screen in year 3 to ensure that hits are valid. We have also acquired an improved RNAi library, which will help facilitate this process (~10 shRNA per gene rather than only 3 for our current one).

KEY RESEARCH ACCOMPLISHMENTS during year 2

- **Isolation and propagation of tumor initiating cells in monolayer culture from 8 pediatric glioma patients**
- **Development and use of methodology for classification of GBM tumors from RNA-seq data**
- **In depth mutation scan and RNA-seq comparisons for 1502 glioma isolate and development of genomics analysis pipeline**
- **Confirmation of GBM-lethal candidates from adult GBM isolate screens in a pediatric GBM isolate**
- **RNAi screen 1502 GSC line for key epigenetic factors required for pediatric glioma stem cell self-renewal**

REPORTABLE OUTCOMES

- manuscripts, abstracts, presentations:

Ding Y et al., Cancer-specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. **Cancer Discov.** 3(2):198-211, 2013

Hubert CG et al., Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. **Genes and Dev.** 27(9):1032-45, 2013
- licenses applied for and/or issued: none during this reporting period
- degrees obtained that are supported by this award: none during this reporting period
- development of cell lines, tissue or serum repositories:

Isolation and propagation of tumor initiating cells from eight pediatric brain tumor patients
- informatics such as databases and animal models, etc.:

Development of methodology for classification of GBM tumors from RNA-seq data and exome sequencing and shRNA screening.
- funding applied for based on work supported by this award: **Pardee Foundation and NIH R01.**

- employment or research opportunities applied for and/or received based on experience/training supported by this award: none during this reporting period



CONCLUSION

In summary, we have made substantial progress towards developing *in vitro* cell models for pediatric brain tumors to identify new therapeutic targets for pediatric glioma for Aims 2 and 3, despite having a few set backs with regard to growth of certain isolates in monolayer culture. However, if progress continues to be made in year 3, we will have at least >3 strong lead candidates for translation into therapeutic development pipelines for treating pediatric glioma as a result of using the pediatric resources developed in this grant.

REFERENCES

1. Cheng, L, Huang, Z, Zhou, W, Wu, Q, Donnola, S, Liu, JK, et al. 2013. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. *Cell* 153(1): 139-52. PMID:23540695, PMCID: PMC3638263
2. Lee, J, Kotliarova, S, Kotliarov, Y, Li, A, Su, Q, Donin, NM, et al. 2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. *Cancer Cell* 9(5): 391-403. PMID:16697959
3. Pollard, SM, Yoshikawa, K, Clarke, ID, Danovi, D, Stricker, S, Russell, R, et al. 2009. Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens. *Cell Stem Cell* 4(6): 568-80. PMID:19497285
4. Singh, SK, Hawkins, C, Clarke, ID, Squire, JA, Bayani, J, Hide, T, et al. 2004. Identification of human brain tumour initiating cells. *Nature* 432(7015): 396-401. PMID:15549107
5. Galli, R, Binda, E, Orfanelli, U, Cipelletti, B, Gritti, A, De Vitis, S, et al. 2004. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. *Cancer Res* 64(19): 7011-21. PMID:15466194
6. Wang, R, Chadalavada, K, Wilshire, J, Kowalik, U, Hovinga, KE, Geber, A, et al. 2010. Glioblastoma stem-like cells give rise to tumour endothelium. *Nature* 468(7325): 829-33. PMID:21102433
7. Ricci-Vitiani, L, Pallini, R, Biffoni, M, Todaro, M, Invernici, G, Cenci, T, et al. 2010. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. *Nature* 468(7325): 824-8. PMID:21102434
8. Verhaak, RG, Hoadley, KA, Purdom, E, Wang, V, Qi, Y, Wilkerson, MD, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* 17(1): 98-110. PMID:20129251, PMCID: PMC2818769
9. Lottaz, C, Beier, D, Meyer, K, Kumar, P, Hermann, A, Schwarz, J, et al. 2010. Transcriptional profiles of CD133+ and CD133- glioblastoma-derived cancer stem cell lines suggest different cells of origin. *Cancer Res* 70(5): 2030-40. PMID:20145155
10. Phillips, HS, Kharbanda, S, Chen, R, Forrest, WF, Soriano, RH, Wu, TD, et al. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 9(3): 157-73. PMID:16530701
11. Trapnell, C, Roberts, A, Goff, L, Pertea, G, Kim, D, Kelley, DR, et al. 2012. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 7(3): 562-78. PMID:22383036
12. Anders, S. HTSeq: Analysing high-throughput sequencing data with Python. 2010 [updated 2010; cited]; Available from: <http://www-huber.embl.de/users/anders/HTSeq/>.
13. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2011.
14. Robinson, MD, McCarthy, DJ, Smyth, GK. 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 26(1): 139-40. PMID:19910308, PMCID: PMC2796818
15. Robinson, MD, Smyth, GK. 2007. Moderated statistical tests for assessing differences in tag abundance. *Bioinformatics* 23(21): 2881-7. PMID:17881408
16. Robinson, MD, Smyth, GK. 2008. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. *Biostatistics* 9(2): 321-32. PMID:17728317
17. Ding, Y, Hubert, CG, Herman, J, Corrin, P, Toledo, CM, Skutt-Kakaria, K, et al. 2013. Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. *Cancer discovery* 3(2): 198-211. PMID:23154965, PMCID: PMC3632446
18. Hubert, CG, Bradley, RK, Ding, Y, Toledo, CM, Herman, J, Skutt-Kakaria, K, et al. 2013. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. *Genes Dev* 27(9): 1032-45. PMID:23651857, PMCID: PMC3656321

SUPPORTING DATA






Figure 3. Genome-wide screens from [18] in patient-derived GBM stem-like cells and control neural stem cells revealed an novel candidate ZNF131 (A). ZNF131 was further validated in outgrowth assays for viability using both adult and pediatric GSCs (B). ZNF131 showed specific lethality in tumor isolates. Pediatric isolate 1502 is highlighted in red-hashes. Note that KIF11 knockdown acts as an essential gene control and the CB660 and 779TL are both human fetal neural stem cell isolates used as candidate cell-of-origin controls for GSCs.

Table 1: Results from a shRNA screen comparing adult and pediatric GSCs to NSCs, attempting to identify new therapeutic targets from among 319 epigenetic regulatory factors.

Gene	Predicted Function	shRNAs scoring	Specificity?
ASH2L	Set1-like multiprotein histone methyltransferase complex	3	Adult/Pediatric
DPY30	Set1-like multiprotein histone methyltransferase complex	4	Pediatric
KAT5	Histone acetyltransferase	3	Pediatric
KAT8	Histone acetyltransferase H4K16ac	4	Pediatric
PARP2	Poly ADP-ribosyl transferase-like 2 protein	3	Pediatric
PBRM1	Protein polybromo-1	4	Pediatric
PRDM11	PR Domain-Containing Protein 11	4	Pediatric
SIN3B	Transcriptional repressor	4	Pediatric
SIRT7	NAD ⁺ -dependent deacetylase	4	Adult/Pediatric
USP22	Deubiquitinating enzyme	4	Pediatric